Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human papillomavirus 15-valent vaccine
- Development stage
- Unknown
- Lead developer
- Beijing Health Guard Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The human papillomavirus 15-valent vaccine (KR-001) is a recombinant virus-like particle (VLP) vaccine developed by Beijing Konruns Biological Technology. It is designed to provide broad-spectrum protection against human papillomavirus (HPV) infection and its associated malignancies, including cervical, vaginal, vulvar, and anal cancers, as well as genital warts. The vaccine targets 15 distinct HPV genotypes: the nine types covered by existing 9-valent vaccines (6, 11, 16, 18, 31, 33, 45, 52, and 58) plus six additional high-risk types (35, 39, 51, 56, 59, and 68). By utilizing a yeast-based expression system (typically *Hansenula polymorpha*) to produce L1 capsid proteins that self-assemble into non-infectious VLPs, the vaccine induces a robust neutralizing antibody response. This expanded valency aims to increase the coverage of HPV-related cancers, particularly in regions where the additional six types are prevalent.
- Other names
- 15-valent HPV vaccine15vHPV
02
Targets
Human papillomavirus type 59 L1 capsid proteinHPV52 L1 (Human papillomavirus type 52 major capsid protein L1)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)HPV45 L1HPV16 (Human papillomavirus type 16)Human papillomavirus type 51 L1 capsid proteinHPV33 L1Human papillomavirus type 39 L1 capsid proteinHuman papillomavirus type 56 L1 capsid proteinHPV58 L1 (Human papillomavirus type 58 major capsid protein L1)HPV11 L1Human papillomavirus type 31 L1 capsid proteinHuman papillomavirus type 35 L1 capsid proteinHPV18 L1
Beyond the preview
Go deeper on human papillomavirus 15-valent vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human papillomavirus 15-valent vaccine.